A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Clinical trial NCT02657369 · TERMINATED

Trial details

NCT number: NCT02657369
Sponsor: Eisai Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Thyroid Carcinoma, Anaplastic

Start date: 2016-07-07
Primary completion: 2018-09-26
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.